English
Regional settings| Spread | 6.30 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ €5,000.00 Short position overnight fee ~ €4,000.00 | -0.022091% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ €5,000.00 Short position overnight fee ~ €4,000.00 | -0.000132% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | EUR | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | Germany | ||||
| Commission on trade1 | 0% |
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 226.05 |
| Open | 226.05 |
| 1-Year Change | -18.98% |
| Day's Range | 213.6 - 226.05 |
Sartorius AG is a Germany-based supplier of pharmaceutical and laboratory equipment. It operates through two segments: Bioprocess Solutions and Lab Products and Services. The Bioprocess Solutions segment offers integrated solutions for biopharmaceutical manufacture, such as filters for sterilization of biopharmaceutical media, single-use bags for cell cultivation and storage of biopharmaceuticals, membrane adsorbers for purification in bioprocesses, and filter technology for clarification, among others. The Lab Products and Services segment provides instruments, consumables and services for laboratories, including laboratory balances, laboratory water systems for storage of purified water, electronic pipettes, filter systems for sample preparation and membrane filter systems for sterility testing of parenterals.
BRIEF: For the fiscal year ended 31 December 2021, Sartorius AG revenues increased 48% to EUR3.45B. Net income increased 52% to EUR318.9M. Revenues reflect Bioprocess Solutions segment increase of 53% to EUR2.73B, Lab Products and Services segment increase of 31% to EUR722.2M, Europe (Region)-Germany (Country)-France (Country) segment increase of 53% to EUR1.05B, United States (Country) segment increase of 41% to EUR1.06B.
6/2016, Scrip Issue, 3 new share for every 1 share held (Factor: 4).
